3089 Symptom analysis and quality of life (QoL) in patients treated with nivolumab (NIVO) as ≥2nd line therapy for advanced non-small cell lung cancer (aNSCLC). (September 2015) - Schwartzberg, L.; Chandler, J.; Reynold, C.; Garon, E.B.; Stepanski, E.J.; Keogh, G.P.; Blankstein, K.; Schneider, J.; Korytowski, B.; Sen, R.; Coon, C.; McDonald, J.; et al.